cas 854515-52-9|| where to buy 6-hydroxy-2-methylbenzofuran-3-carboxylic acid

Nombre del producto:6-hydroxy-2-methylbenzofuran-3-carboxylic acid

IUPAC Name:6-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid

Unidad de embalaje	Stock disponible	Precio($)
CM132795-100mg	in stock	ȦȌƋ
CM132795-250mg	in stock	ȷƋǆ
CM132795-1g	in stock	Ƥȷȷ
CM132795-5g	in stock	ȷƤǲƤ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 854515-52-9 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :854515-52-9; Fórmula molecular:C10H8O4; Punto de fusión:-; Código de sonrisas:CC1=C(C(O)=O)C2=C(O1)C=C(O)C=C2; Densidad:

: Número de catálogo:CM132795; Peso molecular:192.17; Punto de ebullición:235.838°C at 760 mmHg; Nº Mdl:MFCD12547297; Almacenamiento:Store at 2-8°C.

: Benzofurans; Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.; Benzofuran | C8H6O | CID 9223 -Chemenu; Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans; Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

: Fruquintinib; November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.